Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nutrients ; 12(4)2020 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-32272659

RESUMEN

Numerous benefits are attributed to omega-3 fatty acids (OM3) especially in cardiovascular health. However, bioavailability and clinical efficacy depend on numerous factors, including OM3 form, food matrix effects (especially the lipid content of the diet), and metabolic capacity. Here, we show in humans that a "pre-digested" OM3-sn-1(3)-monoacylglycerol lipid structure (OM3-MAG) has a significantly greater absorption at high therapeutic doses (2.9 g/day) than the most commonly OM3-ethyl ester (3.1 g/day) form (used for the treatment of hypertriglyceridemia), and a comparable profile to other pre-digested OM3 free fatty acids (OM3-FFA) structure (3.2 g/day). Nutritional supplement doses of MAG resulted in similar increases in OM3 blood level, compared to OM3 triacylglycerols (OM3-TAG) supplements in obese subjects (1.2 g/day) under low fat diet, and in children with cystic fibrosis (1.0 g/day). These results suggest that both forms of pre-digested OM3-MAG and OM3-FFA are effectively absorbed and re-incorporated effectively into triacylglycerols inside the enterocytes, before being exported into the chylomicrons lipid transport system. The pre-digested OM3-MAG might provide a more effective therapy in severe cardiovascular conditions where high doses of OM3 are required and a low-fat diet is indicated, which limited digestive lipase activity.


Asunto(s)
Fibrosis Quística/tratamiento farmacológico , Suplementos Dietéticos , Ácidos Grasos Omega-3 , Hipertrigliceridemia/tratamiento farmacológico , Monoglicéridos , Obesidad/tratamiento farmacológico , Adulto , Disponibilidad Biológica , Quilomicrones/metabolismo , Fibrosis Quística/sangre , Fibrosis Quística/patología , Enterocitos/metabolismo , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/farmacocinética , Femenino , Humanos , Hipertrigliceridemia/sangre , Hipertrigliceridemia/patología , Masculino , Persona de Mediana Edad , Monoglicéridos/administración & dosificación , Monoglicéridos/farmacocinética , Obesidad/sangre , Obesidad/patología , Triglicéridos/sangre
2.
J Cyst Fibros ; 4(4): 227-31, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16081326

RESUMEN

INTRODUCTION: Acquisition of Pseudomonas aeruginosa (PA) in the lungs of patients with cystic fibrosis (CF) is a marker of poor survival. PA is a ubiquitous pathogen prevalent in humid conditions. This study aimed to identify the prevalence of PA in public swimming pools, as well as from water taps. METHODS: Water was collected from public indoor and outdoor pools in the area of St. Gallen, Switzerland. In addition, standing and running water was sampled from bathroom water taps of 50 patients with CF. RESULTS: Outdoor pools: In 2002, none of the 72 specimens from 28 pools revealed PA. In 2003, three specimens from 46 pools (7%) revealed PA, each were from a different paddling pool. Indoor pools: two of 128 specimens from 56 pools (4%) identified PA, both were from non-public hydrotherapy pools. Water taps: in winter, none of the 102 specimens was colonized with PA. in summer, only two out of 50 specimens of the standing water were positive for PA but none of the running water revealed PA. CONCLUSION: The prevalence of PA in public swimming pools and bathroom water taps in the eastern part of Switzerland is very low. On hot summer days, outdoor paddling pools and standing tap water can contain PA. This study does not support recommendations to avoid public swimming pools or running tap water if the water is maintained according to hygiene guidelines.


Asunto(s)
Fibrosis Quística , Agua Dulce/microbiología , Pseudomonas aeruginosa/aislamiento & purificación , Piscinas/normas , Abastecimiento de Agua , Recuento de Colonia Microbiana , Humanos , Hidroterapia/efectos adversos , Pseudomonas aeruginosa/patogenicidad , Factores de Riesgo , Suiza
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA